22^nd Century Group, the biotech company that entered the cannabis space in 2014 with ambitions to monetize cannabis genetics, is abandoning the effort.  In 2018, they doubled down on the emerging hemp sector, seeing opportunity in bioinformatics and gene editing.  The company is now shedding its cannabis operations, GVB Pharma, selling to Nevada-based Specialty Acquisition Corporation for $2.25 million.

…